STAT Plus: After an unprecedented death, FDA is offered divergent forecasts on future of fecal transplants
They may be unparalleled lifesavers. Or they may be keeping lifesaving drugs off the market.
For more than three hours on Monday, FDA officials heard dramatically different forecasts for the future of fecal matter transplants, a relatively new therapy that is mostly used to treat recurrent Clostridium difficile infections. The meeting happened less than a week after a paper in the New England Journal of Medicine revealed new details about the first-ever death associated with the procedure.
Continue to STAT Plus to read the full story…
